Preliminary safety and efficacy results from a phase lb study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with the anti-PD-1 mAb CS1003 in patients with advanced solid tumors

Preliminary safety and efficacy results from a phase lb study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with the anti-PD-1 mAb CS1003 in patients with advanced solid tumors

Ivosidenib in Chinese patients with relapsed/refractory acute myeloid leukemia (R/R AML) with an IDH1 mutation: results from a bridging registrational study

Abstract 519 Ivosidenib in Chinese patients (pts) with relapsed/refractory acute myeloid leukemia (R/R AML) with an IDH1 mutation: results from a bridging registrational study

GEMSTONE-301: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Sugemalimab in Patien Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Concurrent or Sequential Chemoradiotherapy

Abstract 1950 GEMSTONE-301: A randomized, double-blind, placebo-controlled, phase 3 study of sugemalimab in patients withunresectable stage III non-small cell lung cancer (NSCLC) who had not progressed after concurrent or sequentialchemoradiotherapy (CRT)

Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with the anti-PD-1 mAb CS1003 in patients with advanced solid tumors

Safety and Efficacy Results from an Open-label, Multicentre, Phase I/II Study of Avapritinib in Chin Gastrointestinal Stromal Tumor (GIST): A Bridging Study of NAVIGATOR